FDA expands use of Qiagen lung cancer mutation test

By LabPulse.com staff writers

June 2, 2021 -- The U.S. Food and Drug Administration (FDA) approved the expanded use of a Qiagen diagnostic kit as a companion test for the identification of non-small cell lung cancer patients who may be eligible for treatment with a newly approved drug.

Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.

The kit, which will be via Qiagen's Day One Lab Readiness program, is used with the Rotor-Gene Q MDx instrument.

Qiagen inks deal with Mirati on cancer companion diagnostic
Qiagen has announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based, KRAS companion diagnostic to identify patients...
Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...
Qiagen, DiaSorin debut Lyme disease assay
Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin...
Qiagen secures EUA for COVID-19 test
Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for NeuMoDx, a test that helps clinicians distinguish...
Qiagen, Inovio to partner on cervical dysplasia test
Qiagen and Inovio have announced they will develop a next-generation sequencing test for HPV-linked advanced cervical dysplasia that can be used on Illumina's...

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:01:46 PM